TNDM

Tandem Diabetes Care, Inc.

$18.71

2.97%
SectorHealthcareIndustryMedical DevicesCountryUnited States

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems.

Source: Yahoo Finance
AI summary

Price & performance

1M+8.9%
3M-8.2%
YTD-16.5%
1Y+22.6%
52-week range—
Beta1.32
Full chart and returns against a benchmark

Q-Score

52/ 100

Quality against peers; 50 is the peer median.

Growth52
Risk51
Performance51
Valuation56
Profitability57
Leverage38
Sentiment50
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$1B+7.9%
Net income-$204.7M
Net margin-20.2%-10.0 pts
Historical fundamentals

Revenue exposure

30%of revenue from outside the US
United States70%
Non-US30%
Regions, segments, customers and suppliers

Valuation

TNDMIndustryP/E—29.61P/S1.213.49EV/EBITDA—18.38P/B9.673.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 5next report
EPS estimate$-0.24
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate